FILE:LH/LH-8K-20050215072448.txt.gz
EVENTS:	Regulation FD Disclosure
TEXT:
ITEM: Regulation FD Disclosure
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 7.01. Regulation FD Disclosure
Summary information of the Company dated February 15, 2005.
Exhibits
99.1 Press Release dated February 15, 2005
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
8-K Filed February 15, 2005
 
This slide presentation contains forward-looking statements which are subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third- party payors.  Actual results could differ materially from those suggested by these forward-looking statements. Further information on potential factors that could affect the Company's financial results is included in the Company's Form 10-K for the year ended December 31, 2003, and subsequent filings, and will be included in the Company's Form 10-K for the year ended December 31, 2004, when filed.
2
 
The Clinical Laboratory Testing Market - $40 billion Annually
Independent clinical lab share is $16 billion
Represents 2% to 3% of all health care spending
Influences /directs approximately 80% of health care spending
Rapidly evolving technology, emphasis on preventative medicine and aging of population are all driving growth
Has grown at a CAGR of between 5% and 6%
Source:    Company estimates, industry reports and 2003 revenue for LabCorp.
3
 
Profile of LabCorp
A leader in the esoteric and genomic testing market and second-largest clinical laboratory company in North America
Offers more than 4,400 routine and esoteric/genomic tests
Conducts testing on more than 355,000 specimens daily
Provides lab services to more than 220,000 physicians and other health care providers
Approximately 23,500 employees nationwide
4
 
Primary Testing Locations & PSCs
Primary LabCorp Testing Locations
Patient Service Centers
PR
AK
Corporate Headquarters
Burlington, NC
5
 
LabCorp's Investment and Performance Fundamentals
History of Strong Financial Performance
Significant Cash Generator
Industry leading EBITDA margins
Strong Balance Sheet
Investment Grade Credit Ratings
6
 
Net Sales
(in millions)
7
 
EBITDA Margin
8
 
EPS
Note:  All numbers are before the required change in accounting related to the Company's zero-coupon subordinated notes
9
 
Operating Cash Flow
(in millions)
(1) Includes approximately $50 million of benefit from one-time tax credits recorded in 2003.
(1)
10
 
To
lead
the industry in achieving long-term
growth and profitability
by strengthening our
nationwide core testing
business and expanding our
higher-growth, higher-value esoteric and genomic businesses.
LabCorp's Strategy
11
 
Strategic Focus Areas
Scientific
Leadership
Managed
Care
Customer
Retention
-Licensing/partnerships
-Cancer
-Specimen tracking
-Call center consolidation
-Report improvement
-Acquisitions
-Appropriate prices
-Reduce leakage
-Value of new lab tests
-Customer connectivity
12
 
Fourth Quarter Results
(in millions, except per share data)
12/31/03
12/31/04
+/(-)
Revenue
$731.5
$766.5
4.8%
EBITDA
$174.4
$185.0
6.1%
EBITDA Margin
23.8%
24.1%
30
bp
EPS,
before required change in accounting
$0.54
$0.61
13.0%
Reported EPS
$0.52
$0.58
11.5%
13
(1) For definition of EBITDA and a reconciliation to the most comparable measure under Generally Accepted Accounting Principles, see Company's 4th quarter 2004 earnings release furnished on Form 8-K on February 15, 2005.
(2) For a reconciliation of EPS before the required change in accounting to reported EPS, see Company's 4th quarter 2004 earnings release furnished on Form 8-K on February 15, 2005.  
 
Full Year Results
(in millions, except per share data)
2003
2004
+/(-)
Revenue
$2,939.4
$3,084.8
4.9%
EBITDA
$711.5
$787.8
10.7%
EBITDA Margin
24.2%
25.5%
130
bp
EPS,
before required change in accounting
$2.22
$2.58
16.2%
Reported EPS
$2.11
$2.45
16.1%
14
(1) For definition of EBITDA and a reconciliation to the most comparable measure under Generally Accepted Accounting Principles, see Company's 4th quarter 2004 earnings release furnished on Form 8-K on February 15,2005.
(2) For a reconciliation of EPS before the required change in accounting to reported EPS, see Company's 4th quarter 2004 earnings release furnished on Form 8-K on February 15, 2005.  
 
Financial Performance
Price & Volumes:  Trends by Payor Type
Client (Physicians)
Patient
Third Party
(MC/MD/Insurance)
Managed Care
Capitated
Fee for service
Total
LabCorp Total
2002
PPA
$
Accessions
millions
26.27
119.93
31.87
9.28
44.79
30.45
$31.71
29.6
2.3
14.8
13.1
19.3
32.4
79.1
2003
PPA
$
millions
27.07
118.48
34.25
9.95
45.68
32.74
$33.43
31.7
2.5
18.1
12.9
22.7
35.6
87.9
Accessions
YTD 2004
PPA
$
millions
26.61
123.59
34.84
10.36
46.01
33.67
$33.86
32.7
2.5
18.9
12.8
24.2
37.0
91.1
Accessions
15
 
Financial Performance
Revenue Analysis by Business Area
YTD DEC 2003
Revenue
% Accns
Accns
PPA
$Million
to  total
000
$
Genomic
Identity/Gene Probes
All Genomic
Other Esoteric
Histology
All Genomic/         
          
Esoteric
Core
Total
283.2
2,323.9
2.6%
121.86
152.0
435.2
256.0
197.9
889.1
2,050.3
2,939.4
3,533.4
5,857.3
6,243.9
2,175.6
14,276.8
73,638.3
87,915.1
4.0%
6.6%
7.1%
2.5%
16.2%
83.8%
100.0%
43.02
74.30
41.01
90.96
62.28
27.84
33.43
YTD DEC 2004
Revenue
% Accns
Accns
$Million
to  total
000
296.8
2,529.8
2.8%
117.34
168.6
465.5
298.2
195.2
958.9
2,126.0
3,084.8
3,822.1
6,351.9
7,211.1
2,109.5
15,672.5
75,445.1
91,117.6
4.2%
7.0%
7.9%
2.3%
17.2%
82.8%
100.0%
44.12
73.28
41.35
92.53
61.18
28.18
33.86
PPA
$
(3.7%)
2.6%
(1.4%)
0.8%
1.7%
(1.8%)
1.2%
1.3%
04 vs 03
PPA
Incr/(Decr)
16
 
Financial Guidance for 2005
Revenue growth of approximately 7% to 8% compared to 2004, including in-year revenues of $25 to $35 million from small acquisitions and/or new contracts
EBITDA margins in the range of 25.5% to 26.0% of revenues
EPS in the range of $2.87 to $2.92 before the required change in accounting related to the zero-coupon subordinated notes.  After the accounting change, EPS in the range of $2.72 to $2.77
Capital expenditures of between $110 and $125 million
Free cash flow of between $440 and $465 million
17
 
Financial Guidance for 2005 (cont'd.)
Net interest expense of approximately $32 million
A tax rate of approximately 41%, and
Bad debt rate of approximately 5.5% of sales for the year
Guidance does not include:
Share repurchases after December 31, 2004
Major acquisitions, other than US LABS
Possible significant contributions from new tests, and
The impact of new accounting for stock based compensation
18
 
EPS
-
New Accounting for Shares Related to Zero
            
                                 
Coupon-Subordinated Notes
Qtr 1
Qtr 2
Qtr 3
Qtr 4
YTD
2005:
Before
-
-
-
-
$2.87-$2.92
After
-
-
-
-
$2.72-$2.77
2004:
Before
$0.61
$0.70
$0.66
$0.61
$2.58
After
$0.58
$0.66
$0.63
$0.58
$2.45
2003:
Before
$0.51
$0.60
$0.58
$0.54
$2.22
After
$0.48
$0.57
$0.55
$0.52
$2.11
19
Note:  During the fourth quarter of 2004, the Company adopted the provisions of EITF No. 04-8 for its zero coupon-subordinated notes, including the retroactive restatement of all diluted earnings per share calculations for all periods presented.  The table above presents the amounts before and after restatement.  
For a reconciliation of EPS before the required change in accounting to reported EPS for the three and twelve months ended December 31, 2004 and 2003, see Company's 4th quarter 2004 earnings release furnished on Form 8-K on February 15, 2005.  
 
Free Cash Flow Investment Strategy
Acquisitions
Stock repurchase program
Approximately $122 million remaining as of December 31, 2004 under current $250 million authorization
Since 2003, we have repurchased approximately $528 million representing approximately 14.4 million shares
Retain flexibility in utilizing remaining cash
20
 
Other Financial Information
For the Quarter and Year Ended December 31, 2004
Depreciation
Amortization
Capital expenditures
Bad debt as a percentage of sales
Q1
22.9
Zero coupon-subordinated notes
Revolving credit facility   
        
(weighted average)
Cash flows from operations
Effective interest rate on debt:
5 1/2% Senior Notes
(including
      
effect of interest rate swap)
Days sales outstanding
YTD 2004
$
93.0
$
10.3
42.7
20.2
95.0
147.6
538.1
6.75%
6.25%
2.00%
2.00%
5.38%
5.38%
1.95%
2.62%
54
52
$
$
$
$
$
$
($ in millions)
Q2
23.3
$
10.5
22.4
146.7
6.25%
2.00%
5.38%
2.21%
52
$
$
$
Q3
23.5
$
10.9
16.5
137.2
6.25%
2.00%
5.38%
2.62%
52
$
$
$
Q4
23.3
$
11.0
35.9
106.6
5.75%
2.00%
5.38%
2.62%
52
$
$
$
21
 


